Table 2.

Gene mutation analysis in newly diagnosed AML patients with and without BMF.

Gene name	AML with BMF, n (%)	AML without MF, n (%)	P value
FLT3-ITD	21 (16.15%)	8 (13.33%)	0.618
FLT3-TKD	5 (3.85%)	7 (11.67%)	0.054
CEBPA	10 (7.69%)	21 (35%)	0.000
NPM1	20 (15.38%)	6 (10%)	0.287
C-kit	8 (6.15%)	5 (8.33%)	0.583
TP53	5 (3.85%)	2 (3.33%)	0.862
RUNX1	10 (7.69%)	2 (3.33%)	0.190
ASXL1	40 (30.77%)	8 (13.33%)	0.004
DNMT3A	18 (13.85%)	5 (8.33%)	0.244
IDH1	1 (0.77%)	3 (5%)	0.155
IDH2	6 (4.62%)	2 (3.33%)	0.684
SF3B1	3 (2.31%)	2 (3.33%)	0.683
U2AF1	9 (6.92%)	3 (5%)	0.615
SRSF2	7 (5.38%)	3 (5%)	0.913
ZRSR2	1 (0.77%)	2 (3.33%)	0.301
EZH2	2 (1.54%)	0 (0)	0.337
TET2	83 (63.85%)	29 (48.33%)	0.048
CBL	8 (6.15%)	2 (3.33%)	0.421
JAK2/V617F	8 (6.15%)	1 (1.67%)	0.097
NRAS	30 (23.08%)	9 (15.00%)	0.177
KRAS	1 (0.77%)	0 (0)	0.498
ETV6	4 (3.08%)	4 (6.67%)	0.320
SETBP1	6 (4.62%)	1 (1.67%)	0.318
GATA2	1 (0.77%)	1 (1.67%)	0.576
IKZF1	0 (0)	1 (1.67%)	0.321

AML, acute myeloid leukemia; BMF, bone marrow fibrosis.